Biodesix $50 million at-the-market offering
Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by Biodesix, Inc. of shares of its common stock for up to a maximum offering price of $50 million. The shares of common stock are listed on the Nasdaq Global Market under the symbol “BDSX.”
Biodesix, headquartered in Boulder, Colorado, is a data-driven diagnostic solutions company leveraging state of the art technologies with its proprietary artificial intelligence platform to discover, develop and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. In addition to diagnostic tests, Biodesix provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing and the discovery, development and commercialization of companion diagnostics.
The Davis Polk capital markets team included partner Richard D. Truesdell Jr. and counsel Alain Kuyumjian. The intellectual property and technology transactions team included partner David R. Bauer and associate Brette L. Trost. The tax team included counsel Alon Gurfinkel and associate Justin Corvino. Members of the Davis Polk team are based in the New York and London offices.